Bio-Reference Laboratories, Inc. Announces That Robert Daber, Ph.D. Will Join Company as Director of R&D and Cancer Genetics

Bio-Reference Laboratories, Inc. Announces That Robert Daber, Ph.D. Will Join
Company as Director of R&D and Cancer Genetics

Former University of Pennsylvania Technical Director of Clinical Genetics Will
Lead BRLI Cancer Genetics Program

ELMWOOD PARK, N.J., April 16, 2014 (GLOBE NEWSWIRE) -- Bio-Reference
Laboratories, Inc. (Nasdaq:BRLI) announced today that it has hired Robert
Daber, Ph.D. to assume the dual role as Director of Research and Development
and Director of Cancer Genetics at its Elmwood Park international
headquarters. BRLI has been an industry leader in clinical diagnostics
primarily as a result of its ongoing development of innovative testing based
on new and emerging technology.Dr. Daber will take over leadership of this
pioneering process along with his directorship of the cancer genetics program
at BRLI.

Prior to taking on his new role at BRLI, Dr. Daber had been the Technical
Director of Clinical Genetics at the University of Pennsylvania in
Philadelphia, PA, since 2011.While at the University of Pennsylvania, he
pioneered one of the earlier CAP/CLIA compliant cancer genomics diagnostic
laboratories where he was responsible for the development of Next Generation
(NextGen) Sequencing Clinical Tests, along with associated methodologies and
bioinformatics.During his tenure he reviewed genomic profiles for over 2000
tumors and developed novel bio-informatics approaches to improve assay
sensitivity.Prior to that, Dr. Daber was a Post Doctoral Fellow at the
Children's Hospital of Philadelphia (CHOP) where he worked with a variety of
techniques, platforms and tools to design and develop efficient tests and
testing algorithms in molecular diagnostics.Dr. Daber graduated from the
University of Maryland Baltimore County with a Bachelor of Science in
Biochemistry and Applied Molecular Biology before earning his Ph.D. in
Biochemistry and Molecular Biophysics at the University of Pennsylvania School
of Medicine.He is Board certified in Clinical Cytogenetics by the American
Board of Medical Genetics (ABMG).

Marc D. Grodman, MD, CEO, commented: "Cancer Genetics, which includes
understanding the mutational status of a patient's individual tumor, holds
great promise for both finding the right therapeutic and improving outcomes.
Moreover, it also creates a challenge to find reimbursement levels that
today's payers of all kinds can endorse. We have a vision for tumor
genotyping: it has to demonstrate clinical utility, meet the highest standards
of clinical validity and be cost effective. Bob Daber not only shares this
vision, but he has already made it a reality in his career. Building upon our
extensive capabilities and our collaboration with the Massachusetts General
Hospital Cancer Center, we remain committed to providing the best alternatives
for both those who treat cancer as well as those who develop new anti-cancer

About Bio-Reference Laboratories, Inc.

BRLI is a clinical testing laboratory offering testing, information and
related services to physician offices, clinics, hospitals, employers and
governmental units.We believe that we are the fourth largest full-service
laboratory in the United States and the largest independent regional
laboratory in the Northeastern market.BRLI offers a comprehensive list of
laboratory testing services utilized by healthcare providers in the detection,
diagnosis, evaluation, monitoring and treatment of diseases. BRLI primarily
focuses on esoteric testing, molecular diagnostics, anatomical pathology,
women's health and correctional health care.

Statements included in this release that are not historical in nature, are
intended to be, and are hereby identified as "forward-looking statements".
Forward-looking statements may be identified by words such as "expects,"
"anticipates," "intends," "plans," "believes," "seeks," "estimates," "will" or
words of similar meaning and include, but are not limited to, statements about
the expected future business and financial performance of Bio-Reference
Laboratories,Inc. and its subsidiaries. Statements looking forward in time
are included in this release pursuant to the "safe harbor" provisions of the
Private Securities Litigation Reform Act of 1995. Readers are cautioned not to
place undue reliance on forward-looking statements, which speak only as of the
date they are made and which reflect management's current estimates,
projections, expectations or beliefs and which involve risks and uncertainties
that could cause actual results and outcomes to be materially different.Risks
and uncertainties that may affect the future results of the company include,
but are not limited to, adverse results from pending or future government
investigations, our ability to sustain continued growth, lawsuits or private
actions, including the action involving Horizon Blue Cross Blue Shield of New
Jersey, the competitive environment, changes in government regulations,
changing relationships with customers, payers, including the various state and
multi-state Blues programs, suppliers and strategic partners, the ability to
increase revenue through our prior expansions, the successful roll-out of our
inherited cancer tests launched by GeneDx and other risks and uncertainties
detailed from time to time in our filings with the Securities and Exchange
Commission.We undertake no obligation to publicly update or review any
forward-looking information, whether as a result of new information, future
developments or otherwise.


CONTACT: Tara Mackay, Investor Relations
         (201) 791-2600
         (201) 791-1941 (fax)

Bio-Reference Laboratories, Inc. logo
Press spacebar to pause and continue. Press esc to stop.